A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Semaglutide Subcutaneous Depot (CAM2056) in People with Obesity or Overweight

Condition studied

Body weight management

Investigational medicinal product(s)

Eligibility

Primary endpoint

Relative change in body weight from baseline to Week 36.

Endpoint detail

Relative change in body weight from baseline to Week 36., Relative change in body weight from baseline to Week 12 and Week 24., Response status at Week 12, Week 24, and Week 36, defined by relative body weight reduction from baseline of ≥5%, ≥10%, ≥15%, and ≥20%., Change in HbA1c from baseline to Week 12, Week 24, and Week 36., Change in fasting plasma glucose from baseline to Week 12, Week 24, and Week 36., Change in waist circumference from baseline to Week 12, Week 24, and Week 36., Change in systolic and diastolic blood pressure from baseline to Week 12, Week 24, and Week 36, Change in the levels of lipoprotein lipids (total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides) and free fatty acids from baseline to Week 36., Number of participants with TEAEs during the trial